Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. annual/quarterly shareholder equity history from 2020 to 2024. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Inhibikase Therapeutics Inc. shareholder equity for the quarter ending December 31, 2024 were 94.9M, a 764.16% increase year-over-year.
- Inhibikase Therapeutics Inc. shareholder equity for 2024 were 94.9M, a 764.16% increase from 2023.
- Inhibikase Therapeutics Inc. shareholder equity for 2023 were 11.0M, a 47.81% decrease from 2022.
- Inhibikase Therapeutics Inc. shareholder equity for 2022 were 21.0M, a 45.24% decrease from 2021.
- Inhibikase Therapeutics Inc. shareholder equity for 2021 were 38.4M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Inhibikase Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2024 | $95 |
| 2023 | $11 |
| 2022 | $21 |
| 2021 | $38 |
| 2020 | $10 |
| Inhibikase Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2024-12-31 | $95 |
| 2023-12-31 | $11 |
| 2022-12-31 | $21 |
| 2021-12-31 | $38 |
| 2020-12-31 | $10 |
Inhibikase Therapeutics Inc. Shareholder Equity — FAQ
Inhibikase Therapeutics Inc. (IKT) shareholder equity over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's shareholder equity history?
The chart and table above show Inhibikase Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.